Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Sleep-tech company Oventus has received U.S. FDA approval for its sleep apnoea device, O2Vent Optima
  • The approval allows the company to begin selling its product in the U.S. market and launch pre-established supply agreements
  • Shares in Oventus are up 11.46 per cent today, currently trading for $0.54 apiece

Sleep-tech company Oventus has received U.S. FDA approval for its sleep apnoea device, O2Vent Optima.

Getting the all clear from The States’ food and drug regulatory body, this allows the company to begin sales in the U.S. market.

Prior to the O2Vent being cleared by the U.S. federal agency, Oventus established supply agreements with American-based sleep groups, which can now officially launch.

CEO of Oventus Dr Chris Hart said: “We look forward to officially launching our material agreements within US sleep channels and working with our customers across their various treatment sites to deliver Optima devices to patients.”

After achieving regulatory approvals in the U.S., Oventus expects it will fast track its expansion across the The States, Canada and Australia. Over the next 12-24 months, the company is working to secure several supply agreements.

The O2Vent Optima is a custom, 3D-printed nylon oral appliance, resembling a mouthguard in appearance. It is designed to help patients with obstructive sleep apnoea by enabling unobstructed air to flow to the back of the throat.

Multiple clinical studies have proven this technology to be effective with more than 170 patients benefiting from it.

The company highlighted going forward it is secure in scaling sales significantly, due to $9.3 million raised from shareholders earlier in the year.

Shares in Oventus are up 11.46 per cent today, currently trading for $0.54 apiece, as of AEST 11:32 am.

OVN by the numbers
More From The Market Herald
Incannex Healthcare (ASX:IHL)

" Incannex Healthcare (ASX:IHL) engages Procaps to manufacture sleep apnoea treatment

Incannex Healthcare (IHL) has engaged a company to manufacture its soft-gel capsules in preparation for upcoming clinical trials.
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial